Pharmafile Logo
Pharmafocus logo
Advanced Search

Vertex announces positive results from trial for cystic fibrosis combination treatment

February 6, 2024
Research and Development Chronic Diseases, Vertex pharmaceuticals, clinical trial, combination treatment, cystic fibrosis

Vertex Pharmaceuticals has announced positive results from its once-daily vanzacaftor/tezacaftor/deutivacaftor programme, the company’s phase 3 programme for the treatment of …

News

Zuellig Pharma acquires Cialis and Alimta from Eli Lilly in certain ASEAN markets

February 5, 2024
Business Services Cialis, Eli Lilly, Pharmacy, Zuellig Pharma, acquisition

Zuellig Pharma has announced that it has completed the acquisition of two brands Cialis (Tadalafil) and Alita (Pemetrexed) from Eli …

News

Regeneron’s linvoseltamab gains EMA filing acceptance for R/R MM treatment

February 5, 2024
Medical Communications EMA, Oncology, Regeneron, linvoseltamab, multiple myeloma

Regeneron Pharmaceuticals has announced that the European Medicines Agency (EMA) has accepted for review its Marketing Authorisation Application (MAA) for …

News
milad-fakurian-58z17lnvs4u-unsplash_2

Vivet Therapeutics gains €4.9m for gene therapy development

February 2, 2024
Research and Development CTX, Neurology, Vivet Therapeutics, funding, gene therapy

Vivet Therapeutics has announced that it has received €4.9m financing from the French Government for the advanced development of a …

News

AstraZeneca shares results from phase 3 trial of acoramidis in adults with ATTR-CM

February 2, 2024
Research and Development ATTR-CM, AstraZeneca, Cardiology, acoramidis, clinical trial

AstraZeneca has announced positive high-level results from the phase 3 trial of acoramidis in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) …

News

NICE recommends SC treatment of AbbVie’s Tepkinly for patients with DLBCL

February 1, 2024
Medical Communications AbbVie, DLBCL, NICE, Oncology, lymphoma

AbbVie has announced that the National Institute for Health and Care Excellence (NICE) has recommended Tepkinly (epcoritamab) as a treatment …

News
volodymyr-hryshchenko-m1hq4ibp9rc-unsplash

FDA grants ODD to Revolo Biotherapeutics’ eosinophilic esophagitis treatment

February 1, 2024
Medical Communications FDA, ODD, Pharmacy, Revolo Biotherapeutics, eosinophilic esophagitis

Revolo Biotherapeutics has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ‘1104, …

News

MHRA approves GSK’s Omjjara in Great Britain for splenomegaly treatment

January 31, 2024
Medical Communications GSK, MHRA, Omjjara, Oncology, myelofibrosis, splenomegaly

GSK has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted Marketing Authorisation to Omjjara (momelotinib) in …

News
louis-reed-pwckf7l4-no-unsplash_5

Regeneron forms Regeneron Cell Medicines with acquisition of 2seventy bio

January 31, 2024
Business Services 2seventy bio, Pharmacy, Regeneron, Regeneron Cell Medicines, acquisition

Regeneron Pharmaceuticals has announced the formation of Regeneron Cell Medicines based on an agreement with 2seventy bio to acquire the …

News

FDA clears IND for Gracell Biotechnologies’ phase 1 clinical trial for multiple myeloma treatment

January 30, 2024
Research and Development FDA, Gracell Biotechnologies, Oncology, clinical trial, multiple myeloma

Gracell Biotechnologies has announced that the US Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application, …

News

Oxford Biomedica acquires ABL Europe for €15m

January 30, 2024
Business Services ABL Europe, Oxford BioMedica, Pharmacy, acquisition

Oxford Biomedica has announced that it has completed the acquisition of ABL Europe from Institut Mérieux. This follows announcements on …

News

EMA to review GSK’s Arexvy for RSV prevention in adults aged 50-59

January 29, 2024
Medical Communications Arexvy, EMA, Infections and infestations, RSV

GSK has announced that the European Medicines Agency (EMA) has accepted the company’s regulatory application to expand the use of …

News

Vergent Bioscience shares phase 2 data for VGT-309

January 29, 2024
Research and Development Oncology, VGT-309, Vergent Bioscience, lung cancer

Vergent Bioscience has announced new data from a phase 2 trial of VGT-309, the company’s investigational tumour-targeted fluorescent imaging agent. …

News

MHRA approves Mounjaro for diabetes and weight management

January 26, 2024
Medical Communications Diabetes, MHRA, Mounjaro, weight management

The Medicines and Healthcare products Regulatory Agency (MHRA) has announced that it has approved a four-dose version of the diabetes …

News

AbbVie invests $223m in Singapore manufacturing site

January 26, 2024
Manufacturing and Production AbbVie, Pharmacy, Singapore, manufacturing

AbbVie has announced that it has invested $223m in an expansion to its Singapore manufacturing facility. This will create more …

News

Haleon recalls cough syrups due to microbial contamination

January 25, 2024
Medical Communications Haleon, Pharmacy, cough syrup, microbial contamination

The US Food and Drug Administration (FDA) has shared an announcement from Haleon detailing the voluntary recall of eight lots …

News

Alphamab Oncology and 3DMedicines enter licensing agreement with Glenmark Speciality

January 25, 2024
Medical Communications 3DMedicines, Alphamab Oncology, Glenmark Speciality, Oncology, envafolimab

Alphamb Oncology and 3DMedicines have announced that they have entered into a license agreement with Glenmark Speciality, a subsidiary of …

News

Futura Medical appoints Roy Davis as non-executive director

January 25, 2024
Business Services Futura Medical, Roy Davis, appointment, non-executive director

Futura Medical has announced the appointment of Roy Davis as non-executive director effective immediately. Roy has extensive commercial experience in …

Appointment

Cellular Origins appoints Peter Crossley as chief operating officer

January 25, 2024
Business Services Cellular Origins, Peter Crossley, appointment, chief operating officer

Cellular Origins, a TTP Company, has announced that it has appointed Peter Crossley as chief operating officer (COO). Peter brings …

Appointment

BenevolentAI appoints Dr Joerg Moeller as CEO

January 25, 2024
Business Services BenevolentAI, CEO, Dr Joerg Moeller, appointment

BenevolentAI has announced that it has appointed Dr Joerg Moeller MD PhD as chief executive officer and executive board member …

Appointment

Latest content

GSK pledges £45m to Fleming Initiative to fight AMR

May 16, 2024

NeuroSense partners with PhaseV on upcoming phase 3 ALS trial

May 16, 2024

AstraZeneca adds new heart failure target through collaboration with BenevolentAI

May 15, 2024

FDA approves Roche’s HPV self-collection screening option

May 15, 2024

NHS accepts Pfizer’s tafamidis for ATTR-CM treatment

May 14, 2024